Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Allakos Inc
ALLK | US
0.85
USD0.19
29.29%
ALLK | US
About Allakos Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.85
Open
0.67
High
0.89
Low
0.67
Allakos Inc. a clinical stage biopharmaceutical company develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy inflammatory and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002) which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease chronic urticaria severe allergic conjunctivitis and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition Allakos Inc. is conducting preclinical studies for AK007 which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos California.
View LessALLK | US
Risk
122.3
Sharpe
-0.55
Luna's Score
46/100
Recommendation
Hold
Luna says (ALLK | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
156.8%1 month
122.3%3 months
102.8%6 months
99.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.70
Debt to equity
0.47
Debt to assets
0.25
Ent. to EBITDA
-0.50
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-182.51M
MarketCap
75.82M
MarketCap(USD)
75.82M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-121.54
Short ratio
5.71
Short perc.
3.18
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.26
Range1M
0.35
Range3M
0.42
Volumes: Market Activity
Rel. volume
3.84
Price X volume
1.14M
